ScholarIQanswers from OpenAlex & ORCID
Amber Rathor
ResearcherPublications, citations & collaboration network
Amber Rathor is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Amber Rathor have?
ScholarIQindexed works
Amber Rathor has 8 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Amber Rathor have?
ScholarIQcitation count
Amber Rathor has 27 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Amber Rathor?
ScholarIQh-index
Amber Rathor has an h-index of 3 in OpenAlex.
What is the i10-index of Amber Rathor?
ScholarIQi10-index
Amber Rathor has an i10-index of 1 in OpenAlex.
What is the ORCID of Amber Rathor?
ScholarIQorcid
The ORCID for Amber Rathor is on the source record.
What is the OpenAlex record for Amber Rathor?
ScholarIQopenalex
The OpenAlex for Amber Rathor is on the source record.
What are the most-cited papers on Amber Rathor?
ScholarIQmost cited works
Mapping the immune landscape in small cell lung cancer by analysing expression of immuno-modulators in tissue biopsies and paired blood samples
Rimlee Dutta, Amber Rathor, Hanuman Prasad Sharma, Hem Chandra Pandey, Prabhat Singh Malik, Anant Mohan, Aruna Nambirajan, Rajeev Kumar, Deepali Jain
Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer
Shilpi Thakur, Amber Rathor, Surabhi Jain, Surabhi Jain, Aruna Nambirajan, Sachin Khurana, Prabhat Singh Malik, Deepali Jain
‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma
Amber Rathor, Prabhat Singh Malik, Pranay Tanwar, Sachin Khurana, Hemavathi Baskarane, Deepam Pushpam, Aruna Nambirajan, Deepali Jain
From bench to bedside and beyond: Challenges in direct KRAS targeting
Atish Gheware, Amber Rathor, Deepali Jain
Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy
Aruna Nambirajan, Amber Rathor, Hemavathi Baskarane, Anju Gs, Sachin Khurana, S. Sushmitha, Aparna Sharma, Prabhat Singh Malik, Deepali Jain